Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4C | Q08493 | 3/20 | 0.37 |
| ▸ | BRD4 | O60885 | 4/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 8/20 | 0.35 |
| ▸ | CDK9 | P50750 | 8/20 | 0.35 |
| ▸ | SYK | P43405 | 3/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15210347 | 0.86 | MAPK1 (0.35) | CCNT1CDK9SYKTGFBR1ACVR1 | |
| SCHEMBL10267561 | 0.82 | MAPK1 (0.41) | PDE4CBRD4CCNT1CDK9 | |
| SCHEMBL15210404 | 0.79 | SYK (0.40) | BRD4CCNT1CDK9SYK | |
| SCHEMBL721674 | 0.79 | SYK (0.40) | BRD4CCNT1CDK9SYK | |
| SCHEMBL10266957 | 0.79 | PRKCI (0.41) | PDE4CBRD4 | |
| SCHEMBL723093 | 0.78 | PDE4C (0.55) | PDE4CBRD4SYK | |
| SCHEMBL722998 | 0.74 | PDE4C (0.41) | PDE4CBRD4SYKTGFBR1ACVR1 | |
| SCHEMBL723624 | 0.74 | PDE4C (0.47) | PDE4CBRD4SYK | |
| SCHEMBL15210345 | 0.73 | ROCK2 (0.43) | BRD4SYK | |
| SCHEMBL15210385 | 0.73 | PDE4C (0.46) | PDE4CBRD4SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | claimed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | claimed |
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | claimed |
| EP-2609100-A2 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| WO-2012025187-A2 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | claimed |
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | SYK, FCGRT, SSB | PDE4C 2858/4885BRD4 1150/4885CCNT1 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.